GEN Exclusives

More »

GEN News Highlights

More »
Jan 7, 2008

Magen Licenses Dermatology Assets from Lilly

  • Magen BioSciences is acquiring a series of preclinical compounds from Eli Lilly for dermatology applications. The deal gives Magen exclusive, worldwide rights for the development and commercialization of these candidates.

    The licensed compounds have reportedly shown anti-inflammatory and antiproliferative activities in preclinical models. These properties suggest a number of possible applications to treat common dermatological disorders.

    Magen was founded just last year with headquarters in Waltham, MA, and a focus on dermatology. “This transaction marks a significant milestone in the growth of Magen to become a premier, science-based dermatology company,” remarks Brian M. Gallagher, Ph.D., president and CEO. “We will leverage the prior research done by Lilly's scientists and will dedicate our efforts to continue to advance these assets through the development process.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?